预约演示

Sanofi pledges to keep polio vaccine supplies afloat in India after new approval

2024-04-04

交易

疫苗上市批准

“We wish to assure all stakeholders that there will be no shortage of IPV vaccines in India on our account,” a Sanofi India spokesperson told Fierce Pharma on Thursday.

After press reports flagged the possibility of an inactivated polio vaIPV vaccinesshortage in India, Sanofi saySanofi ready to supply the nation with a newly approved shot.

Thursday, after the company gained an approval for a new polio vaccine, IMOVAX-Polio, Sanofi issued aSanofirance that it will be able to keep providing sufficient supplies. The developments come quickly on the heels of an Economic Times report alleging that a shortage crisis was looming following Sanofi’s decision to shut down certain vaccine manufacturing operations in the country.

Last September, Sanofi revealed plans to discontinue its polio vaccineo shot in India.Sanofi Sanofi

Still, to hear SSanofitell it, India shouldn’t be concerned.

The company’s lSanofiranch remains “dedicated to supporting India’s public health program for polio,” a Sanofi India spokesperson told Fierce Pharma on Thursday. “To ensure that there is no interruption to the availability of IPV vaccines, we have already obtained approvals for our product IMOVAX-Polio,” she added.

Regarding the company’s decision to discontinue its previous polio shot, Sanofi India’s spokesperson poiSanofio the rapidly shifting healthcare environment in the country following the COVID-19 pandemic.IPV vaccines

Amid rising demand for production capacity in India, Sanofi last year optSanofidiscontinue its older polio shot. The company's spokesperson noted that the shot was only filled and packaCOVID-19 pandemicy’s factory in Hyderabad, while the antigens themselves were manufactured in France.

Sanofi and its Indian affiliate Shantha Biotechnics pSanofi to supply polio vaccines for India’s universal immunization program through UNICEF back in 2015.

Sanofi got its hands on Shantha Shantha Biotechnicsench drugmaker’s vapolio vaccines agreed to pay 550 million euros ($784 million) for the Merieux Alliance’s controlling stake in the Indian shot maker.

Sanofiere in India, SanoShantha week called on local drugmakers Cipla and Dr. Reddy’s Laboratories to help sell its central nervous system (CNS) drugs and vaccines in country.

Cipla is slated to mSanofisix Sanofi CNS medicines, including thCiplading epilepsy therapy Frisium, which Sanofi will continue to own, import and manufacture.